Rationale and Design of the STOP-OB Study for Evaluating the Effects of Tofogliflozin and Glimepiride on Fat Deposition in Type 2 Diabetes Patients Treated with Metformin/DPP-4 Inhibitor Dual Therapy

Diabetes Therapy

Volumn 9, Issue 5, 2018, Pages 2117-2125

  Ishihara, Hisamitsu ^a,b   Anai, Motonobu ^c,d   Seino, Hiroaki ^e   Kitazawa, Toru ^f   Ohashi, Hiroshi ^g   Ai, Masumi ^h,i   Inoue, Masahiro ^j   Fujishiro, Midori ^a,b   Inazawa, Takeshi ^k   Kuroda, Hisamoto ^l   Yamada, Masayo ^m  

^a NIHON UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b SURUGADAI NIHON UNIVERSITY HOSPITAL   (Japan)

^c UNIVERSITY OF TOKYO   (Japan)

^d INSTITUTE FOR ADULT DISEASES   (Japan)

^e Seino Clinic   (Japan)

^f TOKYO METROPOLITAN KOMAGOME HOSPITAL   (Japan)

^g Oyama East Clinic   (Japan)

^h Tanaka Clinic   (Japan)

ⁱ TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^j AIKI Bldg   (Japan)

^k TOKYO UNIVERSITY OF SCIENCE   (Japan)

^l Green Clinic   (Japan)

^m YOKOHAMA SAKAE KYOSAI HOSPITAL   (Japan)

more..

Author keywords

Fat deposition; SGLT2 inhibitor; Sulfonylurea; Third line oral drug; Type 2 diabetes mellitus

Indexed keywords

EID: 85054137788     PISSN: 18696953     EISSN: 18696961     Source Type: Journal    
DOI: 10.1007/s13300-018-0491-4     Document Type: Article

References (28)

1. Kanatsuka A, Sato Y, Kawai K, et al. Relationship between the efficacy of oral antidiabetic drugs and clinical features in type 2 diabetic patients (JDDM38). J Diabetes Investig. 2016;7:386–95
2. Tanabe M, Motonaga R, Terawaki Y, Nomiyama T, Yanase T. Prescription of oral hypoglycemic agents for patients with type 2 diabetes mellitus: a retrospective cohort study using a Japanese hospital database. J Diabetes Investig. 2017;8:227–34
3. Edwards KL, Alvarez C, Irons BK, Fields J. Third-line agent selection for patients with type 2 diabetes mellitus uncontrolled with sulfonylureas and metformin. Pharmacotherapy. 2008;28:506–21
4. Ishii H, Ohkubo Y, Takei M, et al. Efficacy of combination therapy with sitagliptin and low-dose glimepiride in Japanese patients with type 2 diabetes. J Clin Med Res. 2014;6:127–32
5. Umayahara R, Yonemoto T, Kyou C, et al. Low-dose glimepiride with sitagliptin improves glycemic control without dose-dependency in patients with type 2 diabetes inadequately controlled on high-dose glimepiride. Endocr J. 2014;61:1163–70
6. Yamaguchi S, Ikejima M, Furukawa A, Abe M, Nakazaki M, Ishihara H. Octreotide for hypoglycemia caused by sulfonylurea and DPP-4 inhibitor. Diabetes Res Clin Pract. 2015;109:e8–10
7. Tsunekawa T, Hayashi T, Suzuki Y, et al. Plasma adiponectin plays an important role in improving insulin resistance with glimepiride in elderly type 2 diabetic subjects. Diabetes Care. 2003;26:285–9
8. Araki T, Emoto M, Konishi T, et al. Glimepiride increases high- density lipoprotein cholesterol via increasing adiponectin levels in type 2 diabetes mellitus. Metabolism. 2009;58:143–8
9. Xu DY, Zhao SP, Huang QX, et al. Effects of glimepiride on metabolic parameters and cardiovascular risk factors in patients with newly diagnosed type 2 diabetes mellitus. Diabetes Res Clin Pract. 2010;88:71–5
10. Katakami N, Kaneto H, Matsuhisa M, Shimomura I, Yamasaki Y. Effects of glimepiride and glibenclamide on carotid atherosclerosis in type 2 diabetic patients. Diabetes Res Clin Pract. 2011;92:e20–2
11. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117–28
12. Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377:644–57
13. Kosiborod M, Cavender MA, Fu AZ, et al. Lower risk of heart failure and death in patients initiated on sodium-glucose cotransporter-2 inhibitors versus other glucose-lowering drugs. Circulation. 2017;136:249–59
14. Suzuki M, Honda K, Fukazawa M, et al. Tofogliflozin, a potent and highly specific sodium/glucose cotransporter 2 inhibitor, improves glycemic control in diabetic rats and mice. J Pharmacol Exp Ther. 2012;341:692–701
15. Kaku K, Watada H, Iwamoto Y, et al. Efficacy and safety of monotherapy with the novel sodium/glucose cotransporter-2 inhibitor tofogliflozin in Japanese patients with type 2 diabetes mellitus: a combined phase 2 and 3 randomized, placebo-controlled, double-blind, parallel-group comparative study. Cardiovasc Diabetol. 2014;13:65
16. Tanizawa Y, Kaku K, Araki E, et al. Long-term safety and efficacy of tofogliflozin, a selective inhibitor of sodium-glucose cotransporter 2, as monotherapy or in combination with other oral antidiabetic agents in Japanese patients with type 2 diabetes mellitus: multicenter, open-label, randomized controlled trials. Expert Opin Pharmacother. 2014;15:749–66
17. Cefalu WT, Leiter LA, Yoon K-H, et al. Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial. Lancet. 2013;382:941–50
18. Ridderstråle M, Andersen RA, Zeller C, et al. Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial. Lancet Diabetes Endocrinol. 2014;2:691–700
19. Nauck MA, Rohwedder K, Del Prato S, et al. Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin. Diabetes Care. 2011;34:2015–22
20. Downes MJ, Bettington EK, Gunton JE, Turkstra E. Triple therapy in type 2 diabetes; a systematic review and network meta-analysis. Peer J. 2015;3:e1461
21. Lozano-Ortega G, Goring S, Bennett HA, Bergenheim K, Sternhufvud C, Mukherjee J. Network meta-analysis of treatments for type 2 diabetes mellitus following failure with metformin plus sulfonylurea. Curr Med Res Opin. 2016;32:807–16
22. Lee CM, Woodward M, Colagiuri S. Triple therapy combinations for the treatment of type 2 diabetes-a network meta-analysis. Diabetes Res Clin Pract. 2016;116:149–58
23. Blonde L, Stenlöf K, Fung A, Xie J, Canovatchel W, Meininger G. Effects of canagliflozin on body weight and body composition in patients with type 2 diabetes over 104 weeks. Postgrad Med. 2016;128:371–80
24. Ohta A, Kato H, Ishii S, et al. Ipragliflozin, a sodium glucose co-transporter 2 inhibitor, reduces intrahepatic lipid content and abdominal visceral fat volume in patients with type 2 diabetes. Expert Opin Pharmacother. 2017;18:1433–8
25. Tobita H, Sato S, Miyake T, Ishihara S, Kinoshita Y. Effects of dapagliflozin on body composition and liver tests in patients with nonalcoholic steatohepatitis associated with type 2 diabetes mellitus: a prospective, open-label, uncontrolled study. Curr Ther Res Clin Exp. 2017;87:13–9
26. Matsuba R, Matsuba I, Shimokawa M, Nagai Y, Tanaka Y. Tofogliflozin decreases body fat mass and improves peripheral insulin resistance. Diabetes Obes Metab. 2018;20:1311–5
27. Blacher J, Agnoletti D, Protogerou AD, et al. Aortic stiffness, inflammation, denutrition and prognosis in the oldest people. J Hum Hypertens. 2012;26:518–24
28. Izumi M, Manabe E, Uematsu S, Watanabe A, Moritani T. Changes in autonomic nervous system activity, body weight, and percentage fat mass in the first year postpartum and factors regulating the return to prepregnancy weight. J Physiol Anthropol. 2016;35:26